Drug Approval | 17 March 2022
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Nebivolol is used alone or together with other medicines to treat high blood pressure
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
It is only the second generic application approved by the USFDA
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia
Tislelizumab is now approved for seven indications in China
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
The product will be manufactured at Lupin’s facility in Goa, India
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
The product will be manufactured at Lupin’s facility in Pithampur, India
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Subscribe To Our Newsletter & Stay Updated
